Europe Blood Transfusion Diagnostics Market

The Europe blood transfusion diagnostics market is expected to grow from US$ 1,272.35 million in 2022 to US$ 1,858.70 million by 2028. It is estimated to grow at a CAGR of 6.5% from 2022 to 2028. 

Rapid Increase in Prevalence of Chronic Diseases Boosts Market Growth

Populations across the world are undergoing many lifestyle changes, leading to a steady increase in the prevalence of chronic medical conditions. Continuous urbanization has been driving people toward sedentary lifestyles. The modernization of various residential, commercial, and industrial facilities has led to a reduction in physical activities among people while they are continuously under stress caused by personal, professional, and societal factors. Blood transfusion is a part of the treatment of chronic diseases such as anemia, cancer (some types), thalassemia, hemophilia, and sickle cell disease. The growing burden of chronic diseases affects public health, societies, and economies. Blood transfusion diagnostics are widely used in various surgical procedures, including cardiac surgeries and other invasive procedures. Chronic diseases, such as cancer, cardiovascular diseases, and renal disorders, are generally treated via surgical procedures, which are associated with a chance of excessive blood loss. Hence, fresh blood is infused into patients to maintain their blood levels. Blood transfusion diagnostics solutions are used during the blood infusion or reinfusion processes. Hence, the blood transfusion diagnostics market in Europe is growing with a rapid increase in the prevalence of chronic diseases. 

Market Overview 

Germany and the UK the key contributors to the blood transfusion diagnostics market in Europe. The market progress in these countries can be ascribed to the rising number of surgeries and transplantation procedures. In Germany, blood transfusion procedures are highly regulated. Blood services are offered by four types of organizations—state blood transfusion services, communal blood transfusion services, commercial blood centers, and plasmapheresis centers (of the plasma fractionation industry). The German Red Cross Blood Transfusion Services, Transfusion Services, and the German Society for Transfusion Medicine and Immunohematology [i.e., Deutsche Gesellschaft für Transfusionsmedizin und Immunhämatologie (DGTI)] are actively involved in providing blood transfusion services in the country. According to OECD Health Statistics, the occurrence of hip replacement surgeries in Germany was at ~315 per 100,000 people in 2019. Moreover, ~227 people per 100,000 were operated for knee replacement in 2019. Per the research article titled “Characteristics of Recipients of Red Blood Cell Concentrates in a German Federal State”, 2020, transfusion rates in Germany are significantly higher with ~50–55 RBCs/1,000 population. In Germany, in 2020, 3,518 organs were transplanted, 502 of which were living-donor transplants. The vast majority of instances (54.3%) include kidney transplants, followed by liver transplants (23.5%), lung (9.8%), heart (9.6%), pancreas (2.6%), and small intestine (0.2%) transplants. Thus, an increasing number of organ transplant procedures propel the number of blood transfusion diagnostics procedures in Germany. 

Europe Blood Transfusion Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

Europe Blood Transfusion Diagnostics Strategic Insights

Strategic insights for the Europe Blood Transfusion Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Blood Transfusion Diagnostics Report Scope

Europe Blood Transfusion Diagnostics Regional Insights

The geographic scope of the Europe Blood Transfusion Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Europe Blood Transfusion Diagnostics Market Segmentation 

The Europe blood transfusion diagnostics market is segmented based on product, application, end user, and country. 

• Based on product, the Europe blood transfusion diagnostics market is bifurcated into instruments & kits and reagents. The instruments & kits segment held the larger market share in 2022.
• Based on application, the Europe blood transfusion diagnostics market is bifurcated into blood grouping and disease screening. The disease screening segment held the larger market share in 2022.
• Based on end user, the Europe blood transfusion diagnostics market is segmented into hospitals, diagnostic laboratories, blood banks, and plasma fractionation companies. The blood banks segment dominated the market in 2022.
• Based on country, the Europe blood transfusion diagnostics market has been categorized into the UK, Germany, France, Italy, Spain, and Rest of Europe. Our regional analysis states that Germany dominated the market in 2022.

Abbott; BAG Diagnostics GmbH; Bio-Rad Laboratories, Inc.; DiaSorin S.p.A.; F. Hoffmann-La Roche Ltd; Grifols, S.A.; Immucor, Inc.; Ortho Clinical Diagnostics (QuidelOrtho Corporation); Quotient Limited; and Thermo Fisher Scientific Inc. are the leading companies operating in the Europe blood transfusion diagnostics market.